Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Analysts

Certara, Inc. (NASDAQ:CERT) has earned a consensus rating of “Hold” from the thirteen analysts that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $8.85.

Several brokerages have commented on CERT. KeyCorp decreased their price objective on shares of Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Monday, April 13th. Barclays decreased their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Stephens decreased their target price on shares of Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Finally, Wall Street Zen cut shares of Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th.

Certara Trading Up 1.4%

Shares of NASDAQ CERT opened at $5.24 on Friday. The firm’s 50 day moving average price is $5.80 and its 200-day moving average price is $7.58. The company has a market cap of $815.19 million, a PE ratio of -52.40 and a beta of 1.53. Certara has a 52-week low of $4.45 and a 52-week high of $13.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88.

Certara (NASDAQ:CERT) last announced its earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The business had revenue of $106.92 million for the quarter, compared to analysts’ expectations of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The firm’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the prior year, the company posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. On average, equities research analysts expect that Certara will post 0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC acquired a new stake in Certara in the first quarter valued at approximately $259,000. Goldman Sachs Group Inc. grew its position in shares of Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after acquiring an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after acquiring an additional 35,954 shares during the last quarter. Jane Street Group LLC grew its position in shares of Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after acquiring an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Certara by 29.3% during the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after acquiring an additional 21,099 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.